The AMPA receptor as a therapeutic target: Current perspectives and emerging possibilities

Future Medicinal Chemistry

Volumn 2, Issue 5, 2010, Pages 877-891

  Mellor, Ian R ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 ADAMANTYLMETHYLAMMONIO) 5 TRIMETHYLAMMONIOPENTANE DIBROMIDE; 1 (4 AMINOPHENYL) 3,4 DIHYDRO 4 METHYL 3 METHYLCARBAMOYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 1,4 BENZODIOXAN 6 CARBOXYLIC ACID PIPERIDIDE; 2 [5 (4 DIMETHYLSULFAMOYLPHENYL) 6,7,8,9 TETRAHYDRO 8 METHYL 2 OXO 1H PYRROLO[3,2 H]ISOQUINOLIN 3 YLIMINOXY] 4 HYDROXYBUTYRIC ACID; 6 (1 IMIDAZOLYL) 7 NITRO 2,3 QUINOXALINEDIONE; 6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; 6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; 6,7 DINITRO 2,3 QUINOXALINEDIONE; [1,2,3,4 TETRAHYDRO 7 (1H IMIDAZOL 1 YL) 6 NITRO 2,3 DIOXO 1 QUINOXALINYL]ACETIC ACID; [[3,4 DIHYDRO 7 MORPHOLINO 2,3 DIOXO 6 (TRIFLUOROMETHYL) 1(2H) QUINOXALINYL]METHYL]PHOSPHONIC ACID; AMP 397 A; AMPA RECEPTOR; AMPA RECEPTOR ANTAGONIST; ARGIOTOXIN 636; CP 465022; CYCLOTHIAZIDE; DIMETHYL[2 [2 (3 PHENYL 1,2,4 OXADIAZOL 5 YL)PHENOXY]ETHYL]AMINE; JORO SPIDER TOXIN 3; JSTX 3; LEVODOPA; MEMANTINE; N [2 [4 (3 THIENYL)PHENYL]PROPYL] 2 PROPANESULFONAMIDE; PHILANTHOTOXIN; RILUZOLE; RPR 117824; SPERMINE; SYM 2206; TALAMPANEL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTICONVULSANT ACTIVITY; BRAIN ISCHEMIA; DRUG RESEARCH; DRUG TARGETING; EPILEPSY; FRAGILE X SYNDROME; HUMAN; MULTIPLE SCLEROSIS; NEURONAL CEROID LIPOFUSCINOSIS; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN PROCESSING; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; REVIEW; SCHIZOPHRENIA; SPINAL CORD INJURY;

ANIMALS; DRUG DISCOVERY; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; NERVOUS SYSTEM DISEASES; RECEPTORS, AMPA; RECEPTORS, GLUTAMATE;

EID: 77953394170     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.27     Document Type: Review

References (124)

1. Pinheiro PS, Mulle C. Presynaptic glutamate receptors. physiological functions and mechanisms of action. Nat. Rev. Neurosci. 9 (6), 423-436 (2008).
2. Collingridge GL, Olsen RW, Peters J, Spedding M. A nomenclature for ligand-gated ion channels. Neuropharmacology 56 (1), 2-5 (2009).
3. Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate receptor ion channels. Pharmacol. Rev. 51 (1), 7-61 (1999).
4. Madden DR. The structure and function of glutamate receptor ion channels. Nat. Rev. Neurosci. 3 (2), 91-101 (2002).
5. Mayer ML. Glutamate receptor ion channels. Curr. Opin. Neurobiol. 15 (3), 282-288 (2005).
6. Palmer CL, Cotton L, Henley JM. The molecular pharmacology and cell biology of αl-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. Pharmacol. Rev. 57 (2), 253-277 (2005).
7. Hansen KB, Yuan H, Traynelis SF. Structural aspects of AMPA receptor activation, desensitization and deactivation. Curr. Opin. Neurobiol. 17 (3), 281-288 (2007).
8. Madden DR. The inner workings of the AMPA receptors. Curr. Opin. Drug Discov. Devel 5 (5), 741-748 (2002).
9. Sobolevsky AI, Rosconi MP, Gouaux E. X-ray structure, symmetry and mechanism of an AMPA-subtype glutamate receptor. Nature 462, 745-756 (2009).
10. Mosbacher J, Schoepfer R, Monyer H, Burnashev N, Seeburg PH, Ruppersberg JP. A molecular determinant for submillisecond desensitization in glutamate receptors. Science 266 (5187), 1059-1062 (1994).
11. Koike M, Tsukada S, Tsuzuki K, Kijima H, Ozawa S. Regulation of kinetic properties of GluR2 AMPA receptor channels by alternative splicing. J. Neurosci. 20 (6), 2166-2174 (2000).
12. Sommer B, Keinanen K, Verdoorn TA et al. Flip and flop: a cell-specific functional switch in glutamate-operated channels of the CNS. Science 249 (4976), 1580-1585 (1990).
13. Zhou QQ, Imbe H, Zou S, Dubner R, Ren K. Selective upregulation of the flip-flop splice variants of AMPA receptor subunits in the rat spinal cord after hindpaw inflammation. Brain Res. Mol. Brain Res. 88 (1-2), 186-193 (2001).
14. Shepherd JD, Huganir RL. The cell biology of synaptic plasticity: AMPA receptor trafficking. Annu. Rev. Cell. Dev. Biol. 23, 613-643 (2007).
15. Malinow R, Malenka RC. AMPA receptor trafficking and synaptic plasticity. Annu. Rev. Neurosci. 25, 103-126 (2002).
16. Seeburg PH. The role of RNA editing in controlling glutamate receptor channel properties. J. Neurochem. 66 (1), 1-5 (1996).
17. Lomeli H, Mosbacher J, Melcher T et al. Control of kinetic properties of AMPA receptor channels by nuclear RNA editing. Science 266 (5191), 1709-1713 (1994).
18. Vollmar W, Gloger J, Berger E et al. RNA editing (R/G site) and flip-flop splicing of the AMPA receptor subunit GluR2 in nervous tissue of epilepsy patients. Neurobiol. Dis. 15 (2), 371-379 (2004).
19. 2+-permeable AMPA receptors in synaptic plasticity and neuronal death. Trends Neurosci. 30 (3), 126-134 (2007).
20. + channel and binding of channel blockers. Biophys. J. 82 (4), 1884-1893 (2002).
21. (2+)-permeable α-amino-3-hydroxy-5-methyl- 4-isoxazolepropionic acid receptors. Proc. Natl Acad. Sci. USA 92 (20), 9298-9302 (1995).
22. Kamboj SK, Swanson GT, Cull-Candy SG. Intracellular spermine confers rectifcation on rat calcium-permeable AMPA and kainate receptors. J. Physiol. 486 (Pt 2), 297-303 (1995).
23. Bowie D, Mayer ML. Inward rectification of both AMPA and kainate subtype glutamate receptors generated by polyamine-mediated ion channel block. Neuron 15 (2), 453-462 (1995).
24. (2+)- permeable AMPA receptors in rat brain by intracellular polyamines generates double rectification. J. Physiol. 486 (Pt 2), 305-312 (1995).
25. 2+ permeability of AMPA receptors in principal neurons and interneurons in rat CNS. Neuron 15 (1), 193-204 (1995).
26. Swanson GT, Kamboj SK, Cull-Candy SG. Single-channel properties of recombinant AMPA receptors depend on RNA editing, splice variation, and subunit composition. J. Neurosci. 17 (1), 58-69 (1997).
27. Imbesi M, Uz T, Manev R, Sharma RP, Manev H. Minocycline increases phosphorylation and membrane insertion of neuronal GluR1 receptors. Neurosci. Lett. 447 (2-3), 134-137 (2008).
28. Catarzi D, Colotta V, Varano F. Competitive AMPA receptor antagonists. Med. Res. Rev. 27 (2), 239-278 (2007).
29. Pitkanen A, Mathiesen C, Ronn LC, Moller A, Nissinen J. Effect of novel AMPA antagonist, NS1209, on status epilepticus. An experimental study in rat. Epilepsy Res. 74 (1), 45-54 (2007).
30. Gormsen L, Finnerup NB, Almqvist PM, Jensen TS. The efficacy of the AMPA receptor antagonist NS1209 and lidocaine in nerve injury pain: a randomized, double-blind, placebo-controlled, three-way crossover study. Anesth. Analg. 108 (4), 1311-1319 (2009).
31. Szenasi G, Vegh M, Szabo G et al. 2, 3-benzodiazepine-type AMPA receptor antagonists and their neuroprotective effects. Neurochem. Int. 52 (1-2), 166-183 (2008).
32. Paternain AV, Morales M, Lerma J. Selective antagonism of AMPA receptors unmasks kainate receptor-mediated responses in hippocampal neurons. Neuron 14 (1), 185-189 (1995).
33. Balannik V, Menniti FS, Paternain AV, Lerma J, Stern-Bach Y. Molecular mechanism of AMPA receptor noncompetitive antagonism. Neuron 48 (2), 279-288 (2005).
34. Rogawski MA. Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2, 3-benzodiazepines. Trends Pharmacol. Sci. 14 (9), 325-331 (1993).
35. Szabados T, Gigler G, Gacsalyi I, Gyertyan I, Levay G. Comparison of anticonvulsive and acute neuroprotective activity of three 2, 3-benzodiazepine compounds, GYKI 52466, GYKI 53405, and GYKI 53655. Brain Res. Bull. 55 (3), 387-391 (2001).
36. Sanchez-Gomez MV, Matute C. AMPA and kainate receptors each mediate excitotoxicity in oligodendroglial cultures. Neurobiol. Dis. 6 (6), 475-485 (1999).
37. Fritsch B, Stott JJ, Joelle Donofrio J, Rogawski MA. Treatment of early and late kainic-acid induced status epilepticus with the noncompetitive AMPA receptor antagonist GYKI 52466. Epilepsia 51 (1), 108-117 (2010).
38. Chimirri A, De Luca L, Ferro S, De Sarro G, Ciranna L, Gitto R. Combined strategies for the discovery of ionotropic glutamate receptor antagonists. ChemMed Chem 4 (6), 917-922 (2009).
39. Lazzaro JT, Paternain AV, Lerma J et al. Functional characterization of CP-465, 022, a selective, noncompetitive AMPA receptor antagonist. Neuropharmacology 42 (2), 143-153 (2002).
40. Menniti FS, Buchan AM, Chenard BL et al. CP-465, 022, a selective noncompetitive AMPA receptor antagonist, blocks AMPA receptors but is not neuroprotective in vivo. Stroke 34 (1), 171-176 (2003).
41. Pelletier JC, Hesson DP, Jones KA, Costa AM. Substituted 1, 2-dihydrophthalazines: potent, selective, and noncompetitive inhibitors of the AMPA receptor. J. Med. Chem. 39 (2), 343-346 (1996).
42. Weiser T, Brenner M, Palluk R et al. BIIR 561 CL: a novel combined antagonist of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors and voltage-dependent sodium channels with anticonvulsive and neuroprotective properties. J. Pharmacol. Exp. Ther. 289 (3), 1343-1349 (1999).
43. Mellor IR, Brier TJ, Pluteanu F et al. Modification of the philanthotoxin-343 polyamine moiety results in different structure-activity profiles at muscle nicotinic ACh, NMDA and AMPA receptors. Neuropharmacology 44 (1), 70-80 (2003).
44. Bolshakov KV, Tikhonov DB, Gmiro VE, Magazanik LG. Different arrangement of hydrophobic and nucleophilic components of channel binding sites in N-methyl-D-aspartate and AMPA receptors of rat brain is revealed by channel blockade. Neurosci. Lett. 291 (2), 101-104 (2000).
45. Stromgaard K, Mellor I. AMPA receptor ligands: synthetic and pharmacological studies of polyamines and polyamine toxins. Med. Res. Rev. 24 (5), 589-620 (2004).
46. Stromgaard K, Jensen LS, Vogensen SB. Polyamine toxins: development of selective ligands for ionotropic receptors. Toxicon 45 (3), 249-254 (2005).
47. Stromgaard K. Natural products as tools for studies of ligand-gated ion channels. Chem. Rec. 5 (4), 229-239 (2005).
48. Tikhonova TB, Tikhonov DB, Magazanik LG. Common binding site for externally and internally applied AMPA receptor channel blockers. J. Mol. Neurosci. 39 (1-2), 169-174 (2009).
49. Mellor IR, Usherwood PN. Targeting ionotropic receptors with polyaminecontaining toxins. Toxicon 43 (5), 493-508 (2004).
50. Andersen TF, Tikhonov DB, Bolcho U et al. Uncompetitive antagonism of AMPA receptors: Mechanistic insights from studies of polyamine toxin derivatives. J. Med. Chem. 49 (18), 5414-5423 (2006).
51. Jensen LS, Bolcho U, Egebjerg J, Stromgaard K. Design, synthesis, and pharmacological characterization of polyamine toxin derivatives: potent ligands for the pore-forming region of AMPA receptors. Chem Med Chem 1 (4), 419-428 (2006).
52. Lipton SA. Pathologically activated therapeutics for neuroprotection. Nat. Rev. Neurosci. 8 (10), 803-808 (2007).
53. Bolshakov K V, Kim KH, Potapjeva NN et al. Design of antagonists for NMDA and AMPA receptors. Neuropharmacology 49 (2), 144-155 (2005).
54. 2+ permeable AMPA receptors in CA1 area of rat hippocampus. Neuroscience 144 (1), 88-99 (2007).
55. Magazanik LG, Buldakova SL, Samoilova MV, Gmiro VE, Mellor IR, Usherwood PN. Block of open channels of recombinant AMPA receptors and native AMPA/kainate receptors by adamantane derivatives. J. Physiol. 505 (Pt 3), 655-663 (1997).
56. Samoilova MV, Buldakova SL, Vorobjev VS, Sharonova IN, Magazanik LG. The open channel blocking drug, IEM-1460, reveals functionally distinct α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptors in rat brain neurons. Neuroscience 94 (1), 261-268 (1999).
57. Lukomskaya NY, Rukoyatkina NI, Gorbunova LV, Gmiro VE, Magazanik LG. Studies of the roles of NMDA and AMPA glutamate receptors in the mechanism of corasole convulsions in mice. Neurosci. Behav. Physiol. 34 (8), 783-789 (2004).
58. Lukomskaya NY, Rukoyatkina NI, Gorbunova LV, Gmiro VE, Bol'shakov K V, Magazanik LG. Comparison of the anticonvulsive activities of organic mono- and dications with their abilities to inhibit NMDA and AMPA glutamate receptors. Neurosci. Behav. Physiol. 34 (2), 181-187 (2004).
59. Jin R, Clark S, Weeks AM, Dudman JT, Gouaux E, Partin KM. Mechanism of positive allosteric modulators acting on AMPA receptors. J. Neurosci. 25 (39), 9027-9036 (2005).
60. Miu P, Jarvie KR, Radhakrishnan V et al. Novel AMPA receptor potentiators LY392098 and LY404187: effects on recombinant human AMPA receptors in vitro. Neuropharmacology 40 (8), 976-983 (2001).
61. O'Neill MJ, Dix S. AMPA receptor potentiators as cognitive enhancers. IDrugs 10 (3), 185-192 (2007).
62. Damgaard T, Larsen DB, Hansen SL, Grayson B, Neill JC, Plath N. Positive modulation of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors reverses sub-chronic PCP-induced deficits in the novel object recognition task in rats. Behav. Brain Res. 207 (1), 144-150 (2010).
63. Liechti ME, Markou A. Role of the glutamatergic system in nicotine dependence: implications for the discovery and development of new pharmacological smoking cessation therapies. CNS Drugs 22 (9), 705-724 (2008).
64. Buckingham SD, Kwak S, Jones AK, Blackshaw SE, Sattelle DB. Edited GluR2, a gatekeeper for motor neurone survival? Bioessays 30 (11-12), 1185-1192 (2008).
65. Kwak S, Hideyama T, Yamashita T, Aizawa H. AMPA receptor-mediated neuronal death in sporadic ALS. Neuropathology DOI 10.1111/j.1440-1789.2009. 01090 (2010) (Epub ahead of print).
66. Kawahara Y, Kwak S. Excitotoxicity and ALS: what is unique about the AMPA receptors expressed on spinal motor neurons? Amyotroph. Lateral Scler. Other Motor Neuron Disord. 6 (3), 131-144 (2005).
67. Kawahara Y, Sun H, Ito K et al. Underediting of GluR2 mRNA, a neuronal death inducing molecular change in sporadic ALS, does not occur in motor neurons in ALS1 or SBMA. Neurosci. Res. 54 (1), 11-14 (2006).
68. Kwak S, Kawahara Y. Deficient RNA editing of GluR2 and neuronal death in amyotropic lateral sclerosis. J. Mol. Med. 83 (2), 110-120 (2005).
69. Lai C, Xie C, McCormack SG et al. Amyotrophic lateral sclerosis 2-deficiency leads to neuronal degeneration in amyotrophic lateral sclerosis through altered AMPA receptor trafficking. J. Neurosci. 26 (45), 11798-11806 (2006).
70. Van Den Bosch L, Van Damme P, Bogaert E, Robberecht W. The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochim. Biophys. Acta 1762 (11-12), 1068-1082 (2006).
71. Albo F, Pieri M, Zona C. Modulation of AMPA receptors in spinal motor neurons by the neuroprotective agent riluzole. J. Neurosci. Res 78 (2), 200-207 (2004).
72. Pascuzzi RM, Shefner J, Chappell AS et al. A Phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. DOI: 19961264 (2009) (Epub ahead of print).
73. Soundarapandian MM, Tu WH, Peng PL, Zervos AS, Lu Y. AMPA receptor subunit GluR2 gates injurious signals in ischemic stroke. Mol. Neurobiol. 32 (2), 145-155 (2005).
74. Nelson KB. Perinatal ischemic stroke. Stroke 38 (2 Suppl.), 742-745 (2007).
75. Fisher RS, van Emde Boas W, Blume W et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 46 (4), 470-472 (2005).
76. Howes JF, Bell C. Talampanel. Neurotherapeutics 4 (1), 126-129 (2007).
77. Savitt JM, Dawson VL, Dawson TM. Diagnosis and treatment of Parkinson disease: molecules to medicine. J. Clin. Invest. 116 (7), 1744-1754 (2006).
78. Konitsiotis S, Blanchet PJ, Verhagen L, Lamers E, Chase TN. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 54 (8), 1589-1595 (2000).
79. Megyeri K, Marko B, Sziray N et al. Effects of 2, 3-benzodiazepine AMPA receptor antagonists on dopamine turnover in the striatum of rats with experimental parkinsonism. Brain Res. Bull. 71 (5), 501-507 (2007).
80. Centonze D, Muzio L, Rossi S et al. Infammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. J. Neurosci. 29 (11), 3442-3452 (2009).
81. Sarchielli P, Greco L, Floridi A, Gallai V. Excitatory amino acids and multiple sclerosis: evidence from cerebrospinal fluid. Arch. Neurol. 60 (8), 1082-1088 (2003).
82. Srinivasan R, Sailasuta N, Hurd R, Nelson S, Pelletier D. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain 128 (Pt 5), 1016-1025 (2005).
83. Pitt D, Werner P, Raine CS. Glutamate excitotoxicity in a model of multiple sclerosis. Nat. Med. 6 (1), 67-70 (2000).
84. Vallejo-Illarramendi A, Domercq M, Perez-Cerda F, Ravid R, Matute C. Increased expression and function of glutamate transporters in multiple sclerosis. Neurobiol. Dis. 21 (1), 154-164 (2006).
85. Bannerman P, Horiuchi M, Feldman D et al. GluR2-free α-amino-3- hydroxy-5-methyl-4-isoxazolepropionate receptors intensify demyelination in experimental autoimmune encephalomyelitis. J. Neurochem. 102 (4), 1064-1070 (2007).
86. Xu GY, Hughes MG, Ye Z, Hulsebosch CE, McAdoo DJ. Concentrations of glutamate released following spinal cord injury kill oligodendrocytes in the spinal cord. Exp. Neurol. 187 (2), 329-336 (2004).
87. McAdoo DJ, Xu G, Robak G, Hughes MG, Price EM. Evidence that reversed glutamate uptake contributes significantly to glutamate release following experimental injury to the rat spinal cord. Brain Res. 865 (2), 283-285 (2000).
88. Wrathall JR, Choiniere D, Teng YD. Dose-dependent reduction of tissue loss and functional impairment after spinal cord trauma with the AMPA/kainate antagonist NBQX. J. Neurosci. 14 (11 Pt 1), 6598-6607 (1994).
89. Wrathall JR, Teng YD, Choiniere D. Amelioration of functional deficits from spinal cord trauma with systemically administered NBQX, an antagonist of non-N-methyl-D-aspartate receptors. Exp. Neurol. 137 (1), 119-126 (1996).
90. Agrawal SK, Fehlings MG. Role of NMDA and non-NMDA ionotropic glutamate receptors in traumatic spinal cord axonal injury. J. Neurosci. 17 (3), 1055-1063 (1997).
91. Li S, Stys PK. Mechanisms of ionotropic glutamate receptor-mediated excitotoxicity in isolated spinal cord white matter. J. Neurosci. 20 (3), 1190-1198 (2000).
92. Colak A, Soy O, Uzun H et al. Neuroprotective effects of GYKI 52466 on experimental spinal cord injury in rats. J. Neurosurg 98 (3 Suppl.), 275-281 (2003).
93. Kanellopoulos GK, Xu XM, Hsu CY, Lu X, Sundt TM, Kouchoukos NT. White matter injury in spinal cord ischemia: protection by AMPA/kainate glutamate receptor antagonism. Stroke 31 (8), 1945-1952 (2000).
94. Brown KM, Wrathall JR, Yasuda RP, Wolfe BB. Glutamate receptor subunit expression after spinal cord injury in young rats. Brain Res. Dev. Brain Res. 152 (1), 61-68 (2004).
95. Nagano I, Murakami T, Shiote M, Abe K, Itoyama Y. Ventral root avulsion leads to downregulation of GluR2 subunit in spinal motoneurons in adult rats. Neuroscience 117 (1), 139-146 (2003).
96. Ferguson AR, Christensen RN, Gensel JC et al. Cell death after spinal cord injury is exacerbated by rapid TNF α-induced trafficking of GluR2-lacking AMPARs to the plasma membrane. J. Neurosci. 28 (44), 11391-11400 (2008).
97. 2+ dysregulation and neuronal death through activation of ionotropic glutamate receptors. Cell Calcium 47 (3), 264-272 (2010).
98. Rosini M, Simoni E, Bartolini M et al. Inhibition of acetylcholinesterase, β-amyloid aggregation, and NMDA receptors in Alzheimer's disease: a promising direction for the multi-target-directed ligands gold rush. J. Med. Chem. 51 (15), 4381-4384 (2008).
99. Cooper JD. Moving towards therapies for juvenile Batten disease? Exp. Neurol. 211 (2), 329-331 (2008).
100. Pears MR, Cooper JD, Mitchison HM, Mortishire-Smith RJ, Pearce DA, Griffin JL. High resolution 1H NMR-based metabolomics indicates a neurotransmitter cycling deficit in cerebral tissue from a mouse model of Batten disease. J. Biol. Chem. 280 (52), 42508-42514 (2005).
101. Chattopadhyay S, Ito M, Cooper JD et al. An autoantibody inhibitory to glutamic acid decarboxylase in the neurodegenerative disorder Batten disease. Hum. Mol. Genet. 11 (12), 1421-1431 (2002).
102. Kovacs AD, Weimer JM, Pearce DA. Selectively increased sensitivity of cerebellar granule cells to AMPA receptor-mediated excitotoxicity in a mouse model of Batten disease. Neurobiol. Dis. 22 (3), 575-585 (2006).
103. Kovacs AD, Pearce DA. Attenuation of AMPA receptor activity improves motor skills in a mouse model of juvenile Batten disease. Exp. Neurol. 209 (1), 288-291 (2008).
104. Chaturvedi HK, Chandra D, Bapna JS. Interaction between N-methyl-D-aspartate receptor antagonists and imipramine in shock-induced depression. Indian J. Exp. Biol. 37 (10), 952-958 (1999).
105. Yilmaz A, Schulz D, Aksoy A, Canbeyli R. Prolonged effect of an anesthetic dose of ketamine on behavioral despair. Pharmacol. Biochem. Behav. 71 (1-2), 341-344 (2002).
106. Zarate CA Jr, Singh JB, Carlson PJ et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 63 (8), 856-864 (2006).
107. Maeng S, Zarate CA Jr, Du J et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of α-amino-3-hydroxy-5- methylisoxazole-4-propionic acid receptors. Biol. Psychiatry 63 (4), 349-352 (2008).
108. Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res. Rev. 61 (2), 105-123 (2009).
109. Chourbaji S, Vogt MA, Fumagalli F et al. AMPA receptor subunit 1 (GluR-A) knockout mice model the glutamate hypothesis of depression. FASEB J. 22 (9), 3129-3134 (2008).
110. Alt A, Nisenbaum ES, Bleakman D, Witkin JM. A role for AMPA receptors in mood disorders. Biochem. Pharmacol. 71 (9), 1273-1288 (2006).
111. Mathew SJ, Manji HK, Charney DS. Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology 33 (9), 2080-2092 (2008).
112. O'Neill MJ, Witkin JM. AMPA receptor potentiators: application for depression and Parkinson's disease. Curr. Drug Targets 8 (5), 603-620 (2007).
113. Sanacora G, Zarate CA, Krystal JH, Manji HK. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat. Rev. Drug Discov. 7 (5), 426-437 (2008).
114. Li X, Tizzano JP, Griffey K, Clay M, Lindstrom T, Skolnick P. Antidepressant-like actions of an AMPA receptor potentiator (LY392098). Neuropharmacology 40 (8), 1028-1033 (2001).
115. Garber KB, Visootsak J, Warren ST. Fragile X syndrome. Eur. J. Hum. Genet. 16 (6), 666-672 (2008).
116. Pilpel Y, Kolleker A, Berberich S et al. Synaptic ionotropic glutamate receptors and plasticity are developmentally altered in the CA1 field of Fmr1 knockout mice. J. Physiol. 587 (Pt 4), 787-804 (2009).
117. Gordon JA. Testing the glutamate hypothesis of schizophrenia. Nat. Neurosci. 13 (1), 2-4 (2010).
118. Wiedholz LM, Owens WA, Horton RE et al. Mice lacking the AMPA GluR1 receptor exhibit striatal hyperdopaminergia and 'schizophrenia-related' behaviors. Mol. Psychiatry 13 (6), 631-640 (2008).
119. Hashimoto K. Microglial activation in schizophrenia and minocycline treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 32 (7), 1758-1759; author reply 1760 (2008).
120. Fujita Y, Ishima T, Kunitachi S et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline. Prog. Neuropsychopharmacol. Biol. Psychiatry 32 (2), 336-339 (2008).
121. Alano CC, Kauppinen TM, Valls AV, Swanson RA. Minocycline inhibits poly (ADP-ribose) polymerase-1 at nanomolar concentrations. Proc. Natl Acad. Sci. USA 103 (25), 9685-9690 (2006).
122. Bleakman D, Alt A, Nisenbaum ES. Glutamate receptors and pain. Semin. Cell. Dev. Biol. 17 (5), 592-604 (2006).
123. Fang L, Wu J, Lin Q, Willis WD. Protein kinases regulate the phosphorylation of the GluR1 subunit of AMPA receptors of spinal cord in rats following noxious stimulation. Brain Res. Mol. Brain Res. 118 (1-2), 160-165 (2003).
124. Hartmann B, Ahmadi S, Heppenstall PA et al. The AMPA receptor subunits GluR-A and GluR-B reciprocally modulate spinal synaptic plasticity and inflammatory pain. Neuron 44 (4), 637-650 (2004).